About Compellis
Compellis Pharmaceuticals is an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity and related disorders. The company reformulates FDA approved products and identifies proprietary delivery methods to treat broad metabolic disorders and improve quality of life.
Mission: Committed to creating medicines that better the quality of life for patients suffering from health-related conditions, illness or disease; and bringing therapies to those that need them as rapidly as possible. Product Focus: Innovative Medicines for: - Obesity - Diabetes - Hypertension Contact: Compellis Pharmaceuticals 141 PowderHouse Blvd. Suite 1 Boston, MA 02144 617-957-9858 (Tel) 617-625-4132 (Fax) info@compellis.co
Latest Company News
October 27, 2008:
Compellis Pharmaceuticals, Inc. Awarded Second Broad Patent from the U.S. Patent Office for Novel Obesity Therapy
Drug blocks olfactory sensory perception and may lead to weight loss (full press release)
January 7, 2008:
Pennington Biomedical Research Institute receives FDA approval to begin Phase I studies of Compellis Pharmaceuticals' novel and patented obesity therapy
Therapy blocks olfactory sensory perception that may lead to a reduction in appetite and cause weight loss
Boston, Mass., January 7, 2008 (full press release)
December 6, 2006:
Compellis Pharmaceuticals Awarded Patent for its Therapeutic Platform for Treating Obesity
Patent covers therapy that blocks olfactory sensory perception which may lead to reduction in appetite and weight loss.
Boston, Mass., December 6, 2006 - (full press release)